This Life Insurance Awareness Month, empower your clients with a first-of-its-kind cancer screening

This Life Insurance Awareness Month, empower your clients with a first-of-its-kind cancer screening

By Grail - 27 September 2023

You already know that life insurance is a simple, affordable way for families to take care of their financial stability. But only 52% of consumers have life insurance policies,¹ and there are 106 million Americans who need new or increased life insurance policies.² That’s why every September is Life Insurance Awareness Month — a time for the industry to come together and share the importance of life insurance and the role it plays in protecting families’ financial security.


What’s a compelling way to capture the attention of new clients? Innovation. That’s why, driven by their commitment to helping clients, several leading life insurance companies are embracing solutions that go beyond traditional coverage — including helping clients be proactive about their health.


Many cancers are discovered in later stages — only after symptoms appear. Adding Galleri®, a multi-cancer early detection test, to other recommended screenings allows you to go beyond what you thought was possible. Galleri screens for a signal shared by more than 50 types of cancer.³ And it’s done in one simple, convenient blood draw.


Only five types of cancer have recommended screening tests.⁴ Your clients deserve more — introduce them to Galleri. By joining the financial protection of life insurance with the first of its kind multi-cancer early detection test, we can evolve the insurance industry.


This Life Insurance Awareness Month, embrace innovation and share Galleri with them. Because treating cancer starts with knowing you have it.


Ready to get started bringing Galleri to your clients? Click here.


Important Safety Information
The Galleri® test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri® test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri® is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri® is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment. Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of “No Cancer Signal Detected” does not rule out cancer. A test result of “Cancer Signal Detected” requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer. If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.
Laboratory/Test Information
GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists (CAP). The Galleri test was developed, and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the Food and Drug Administration. GRAIL’s clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.
1 Limra. Facts About Life 2021 [Internet]. Windsor (CT): Limra [2021, cited 2023 Jun 21]. Available from:
2 Limra. LIAM – LIMRA International Annual Meeting [Internet]. Windsor (CT): Limra; [cited 2023 Jun 21]. Available from:
3 Klein EA, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021;32(9):1167-1177. doi: 10.1016/j.annonc.2021.05.806.
4 US Preventive Services Task Force Recommended Screenings.

Leave a Reply

Your email address will not be published. Required fields are marked *